Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study.

[1]  S. Friis,et al.  Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study , 2018, British Journal of Cancer.

[2]  M. Pike,et al.  Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium , 2017, British Journal of Cancer.

[3]  O. Lavie,et al.  The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. , 2016, European journal of obstetrics, gynecology, and reproductive biology.

[4]  W. Willett,et al.  Origin, Methods, and Evolution of the Three Nurses' Health Studies. , 2016, American journal of public health.

[5]  D. Khabele,et al.  Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records , 2016, BMC Cancer.

[6]  Qiaojia Huang,et al.  Elevated Preoperative Platelet to Lymphocyte Ratio Indicates Poor Survival in Patients with Resected High-grade Serous Ovarian Carcinoma. , 2016, Clinical laboratory.

[7]  B. Karlan,et al.  "Ovarian cancers: Evolving paradigms in research and care": Report from the Institute of Medicine. , 2016, Gynecologic oncology.

[8]  K. Eng,et al.  Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. , 2015, Gynecologic oncology.

[9]  Helena Carreira,et al.  Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) , 2015, The Lancet.

[10]  Henry C Kitchener,et al.  Ovarian cancer , 2014, The Lancet.

[11]  A. Sood,et al.  Platelet effects on ovarian cancer. , 2014, Seminars in oncology.

[12]  S. Baek,et al.  Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets. , 2014, Cancer letters.

[13]  M. Pike,et al.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. , 2014, Journal of the National Cancer Institute.

[14]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[15]  A. Weaver,et al.  Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. , 2013, Gynecologic oncology.

[16]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[17]  S. H. van der Burg,et al.  Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. , 2012, Current pharmaceutical design.

[18]  C. Madeddu,et al.  Inflammation and ovarian cancer. , 2012, Cytokine.

[19]  W. Chiu,et al.  Paraneoplastic thrombocytosis in ovarian cancer. , 2012, The New England journal of medicine.

[20]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[21]  Jeannette Bigler,et al.  Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.

[22]  M. Lishner,et al.  Non‐steroidal anti‐inflammatory drugs for the prevention and treatment of cancer , 2005, Journal of internal medicine.

[23]  Graham A. Colditz,et al.  The Nurses' Health Study: lifestyle and health among women , 2005, Nature Reviews Cancer.

[24]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[25]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[26]  J. Manson,et al.  Physical activity and breast cancer risk in a cohort of young women. , 1998, Journal of the National Cancer Institute.

[27]  P Peduzzi,et al.  Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. , 1995, Journal of clinical epidemiology.

[28]  M. Stampfer,et al.  Test of the National Death Index and Equifax Nationwide Death Search. , 1994, American journal of epidemiology.

[29]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[30]  Y. Miao,et al.  Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. , 2016, Cancer biomarkers : section A of Disease markers.